Value of CA 15-3 determination in the initial management of breast cancer patients

Annals of Oncology

Volumn 20, Issue 5, 2009, Pages 962-964

  Chourin, S ^a   Georgescu, D ^a   Gray, C ^a   Guillemet, C ^a   Loeb, A ^a   Veyret, C ^a   Basuyau, J P ^a  

^a CENTRE HENRI BECQUEREL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CA 15-3 ANTIGEN;

ANTIGEN DETECTION; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER GRADING; CANCER INVASION; CANCER SIZE; CANCER SURVIVAL; DISEASE ACTIVITY; DISEASE FREE SURVIVAL; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REFERENCE VALUE; REPRODUCIBILITY; SURVIVAL TIME;

EID: 65549092842     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp061     Document Type: Article

References (18)

1. ASCO. Clinical practice guidelines for the use of tumour markers in breast and colorectal cancer. J Clin Oncol 1996; 14(10): 2843-2877.
2. ANAES. Marqueurs sériques dans les cancers du sein et les cancers colorectaux. Recommandations et Références médicales. HAS Ed, Saint-Denis, France: Agence Nationale d'Accréditation et d'Evaluation en Santé 1997.
3. Basuyau JP, Blanc-Vincent MP, Bidart JM et al. Summary report of the Standards, Options and Recommendations for the use of serum tumour markers in breast cancer: 2000. Br J Cancer 2003; 89 (Suppl 1): S32-S34 (www.fnclcc.fr).
4. Molina R, Barak V, van Dalen A et al. Tumour markers in breast cancer. European Group on Tumour Markers recommendations 2005. Tumour Biol 2005; 26(6): 281-293.
5. Harris L, Fritsche H, Mennel R et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumour markers in breast cancer. J Clin Oncol 2007; 25(33): 5287-5311.
6. Sturgeon CM, Duffy MJ, Stenman UH et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast and ovarian cancers. Clin Chem 2008; 54(12): E11-e79.
7. Park BW, Oh JW, Kim JH et al. Preoperative CA 15-3 and CEA serum level as predictor for breast cancer outcomes. Ann Oncol 2008; 19(4): 675-681.
8. Horobin JM, Browning MC, McFarlane NP et al. Potential use of tumour marker CA 15-3 in the staging and prognosis of patients with breast cancer. J R Coll Surg Edinb 1991; 36: 219-221.
9. Iaffaioli RV, Caponigro F, Esposito G et al. Impact of preoperative CA 15-3 levels in operable breast cancer. Comparison with tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA). Int J Biol Markers 1991; 6(1): 21-24.
10. McLaughlin R, McGrath J, Grimes H, Given HF. The prognostic value of the tumour marker CA 15-3 at initial diagnosis of patients with breast cancer. Int J Biol Markers 2000; 15(4): 340-342.
11. Canizares F, Sola J, Perez M et al. Preoperative values of CA 15-3 and CEA as prognostic factors in breast cancer: A multivariate analysis. Tumour Biol 2001; 22(5): 273-281.
12. Gion M, Boracchi P, Dittaldi R et al. Prognostic role of serum CA 15-3 in 362 node-negative breast cancer. An old player for a new game. Eur J Cancer 2002; 38(9): 1165-1166.
13. Ebeling FG, Stieber P, Untch M et al. Serum CEA and CA 15-3 as prognostic factors in primary breast cancer. Br J Cancer 2002; 22: 1217-1222.
14. Kumpulainen EJ, Keskikuru R, Johansson RT. Serum tumour marker CA 15-3 and stage are the two most important predictors of survival in primary breast cancer. Breast Cancer Res Treat 2002; 76: 95-102.
15. Molina R, Filella X, Alicarte J et al. Prospective evaluation of CEA and CA 15-3 in patients with locoregional breast cancer. Anticancer Res 2003; 23: 1035-1042.
16. Duffy MJ, Duggan C, Keane R et al. High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: Study of 600 patients with histologically confirmed breast cancer. Clin Chem 2004; 50(6): 559-563.
17. Shering SG, Sherry F, McDermott EW et al. Preoperative CA 15-3 concentrations predict outcome of patients with breast carcinoma. Cancer 1998; 83(12): 2521-2527.
18. O'Hanlon DM, Kerin MJ, Kent P et al. An evaluation of preoperative CA 15-3 measurement in primary breast carcinoma. Br J Cancer 1995; 71(6): 1288-1291.